Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - dimeticone, activated - tablets - 40 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - dimeticone, activated - 1 per cent

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - paroxetine hydrochloride hemihydrate, quantity: 22.88 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; calcium hydrogen phosphate dihydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - aropax is indicated for treatment of major depression and for the prevention of relapse of depressive symptoms; obsessive compulsive disorder and for the prevention of relapse of ocd; panic disorder and for the prevention of relapse of panic disorder; social anxiety disorder/social phobia; generalised anxiety disorder; and posttraumatic stress disorder.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - paroxetine hydrochloride 22.8mg equivalent to 20 mg paroxetine;   - film coated tablet - 20 mg - active: paroxetine hydrochloride 22.8mg equivalent to 20 mg paroxetine   excipient: calcium hydrogen phosphate dihydrate magnesium stearate opadry white ys-1-7003 sodium starch glycolate - aropax is indicated for the treatment of major depressive disorder (mdd). aropax is indicated for the prevention of relapse and also recurrence of further depressive episodes.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - paroxetine hydrochloride hemihydrate, quantity: 34.14 mg (equivalent: paroxetine, qty 30 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; sodium starch glycollate; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; polysorbate 80; macrogol 400 - aropax is indicated for treatment of major depression and for the prevention of relapse of depressive symptoms; obsessive compulsive disorder and for the prevention of relapse of ocd; panic disorder and for the prevention of relapse of panic disorder; social anxiety disorder/social phobia; generalised anxiety disorder; and posttraumatic stress disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - paroxetine hydrochloride hemihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - paroxetine hydrochloride hemihydrate, quantity: 28.51 mg (equivalent: paroxetine, qty 25 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; hypromellose; povidone; silicon dioxide; magnesium stearate; glyceryl behenate; iron oxide red; methacrylic acid copolymer; purified talc; triethyl citrate; titanium dioxide; polysorbate 80; vat red 1; macrogol 400 - aropax cr is indicated for the treatment of major depressive disorder and panic disorder, social anxiety disorder/social phobia and treatment of premenstrual dysphoric disorder. aropax cr has not been evaluated beyond 12 weeks, 10 weeks, 12 weeks and 3 menstrual cycles in controlled clinical trails for the treatment of major depression, panic disorder, social anxiety disorder and premenstrual dysphoric disorder, respectively.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - paroxetine hydrochloride hemihydrate, quantity: 14.25 mg (equivalent: paroxetine, qty 12.5 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; hypromellose; povidone; silicon dioxide; magnesium stearate; glyceryl behenate; iron oxide yellow; methacrylic acid copolymer; purified talc; triethyl citrate; titanium dioxide; sunset yellow fcf; quinoline yellow; polysorbate 80; macrogol 400 - aropax cr is indicated for the treatment of major depressive disorder and panic disorder, social anxiety disorder/social phobia and treatment of premenstrual dysphoric disorder. aropax cr has not been evaluated beyond 12 weeks, 10 weeks, 12 weeks and 3 menstrual cycles in controlled clinical trails for the treatment of major depression, panic disorder, social anxiety disorder and premenstrual dysphoric disorder, respectively.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - paroxetine hydrochloride hemihydrate, quantity: 2.276 mg/ml (equivalent: paroxetine, qty 2 mg/ml) - oral liquid, suspension - excipient ingredients: polacrilin potassium; dispersible cellulose; propylene glycol; glycerol; sorbitol solution (70 per cent) (crystallising); methyl hydroxybenzoate; propyl hydroxybenzoate; sodium citrate dihydrate; citric acid; saccharin sodium; sunset yellow fcf; purified water; flavour; sodium chloride; dimeticonol; peg-4 stearate; silicon dioxide; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate - aropax is indicated for treatment of major depression and for the prevention of relapse of depressive symptoms; obsessive compulsive disorder and for the prevention of relapse of ocd; panic disorder and for the prevention of relapse of panic disorder; social anxiety disorder/social phobia; generalised anxiety disorder; and posttraumatic stress disorder.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

smith_kb -